Vertex holder plans sale of 1,751 shares
Edward Atkinson, a holder of Vertex Pharmaceuticals (VRTX) common stock, has filed a notice of proposed sale of 1,751 common shares through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $806,212.93.
Rhea-AI Filing Summary
Edward Atkinson, a holder of Vertex Pharmaceuticals (VRTX) common stock, has filed a notice of proposed sale of 1,751 common shares through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $806,212.93.
The 1,751 common shares were acquired on 02/10/2026 via restricted stock vesting from the issuer as compensation. The notice also reports that Atkinson sold 2,500 common shares on 11/17/2025 for gross proceeds of $1,086,450.00. Vertex had 253,718,831 common shares outstanding at the time referenced.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock sale is disclosed for Vertex (VRTX) in this Form 144?
What prior Vertex (VRTX) stock sales by Edward Atkinson are reported?
AI-generated analysis. How Rhea-AI works. Not financial advice.